Market research
107.F Bioasis Technologies Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 635K
- P/E ratio
- Not available
- Analyst target
- 0.61
- Dividend yield
- Not available
- Beta
- 0.52
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA09064N1033
- Market cap
- 635K
- P/E ratio
- Not available
- Analyst target
- 0.61
- Dividend yield
- Not available
- Beta
- 0.52
About
About Bioasis Technologies Inc
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 107.F discussion.
5 years, 5 months ago
Bioasis Technologies Inc is currently in a long term uptrend where the price is trading 8.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.0.
Bioasis Technologies Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 352.7% to $898K since the same quarter in the previous year.
Finally, its free cash flow fell by 17.3% to $-860K since the same quarter in the previous year.
Based on the above factors, Bioasis Technologies Inc gets an overall score of 3/5.